Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss

StatusActive, Not Recruiting
PhaseEarly Phase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints: details revised at 8 of 11 entries
    • Site details revised
  2. Primary completion date: Mar 2027 to Sep 2027
    • Study completion date: Mar 2028 to Sep 2028
    v5
  3. Start date changed from estimate of Mar 2025 to Mar 10, 2025v4
  4. Primary completion date: Feb 2027 to Mar 2027
    • Study completion date: Feb 2028 to Mar 2028
    • Start date: Feb 2025 to Mar 2025
    v3
  5. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Jan 2027 to Feb 2027
    • Study completion date: Jan 2028 to Feb 2028
    • Start date: Jan 2025 to Feb 2025
    • Site details revised
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study examines whether adding tirzepatide-a medication that helps with weight loss-after sleeve gastrectomy surgery can help people lose more weight after the surgery; better improve conditions like Type 2 diabetes, high blood pressure, high cholesterol, and sleep apnea after surgery and; whether this causes more complications or side effects compared to surgery alone.
Trial Details
NCT Number NCT06734273
Lead Sponsor Nicholas Skertich
Conditions
(from sponsor)		 Obesity and Obesity-related Medical Conditions
Related terms Obesity
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov